Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab

Cadonilimab is the first bi-specific antibody approved for certain malignancies in June 2022, which has a modified Fc structure to reduce immune-related adverse events. To date, no reports have described Cadonilimab-related toxic epidermal necrolysis (TEN). Here, we report case of TEN-like reactions occurring during treatment hepatocellular carcinoma with combination Lenvatinib and transarterial chemoembolization, successfully treated supplemental Adalimumab. We confirmed as culprit observed significant improvement patient’s condition following Adalimumab treatment. The emphasizes potential risk inducing TEN, suggests that could be favorable option treating refractory TEN.